IP Library Granted Patent US 11,324,772
Granted Patent B2
US 11,324,772 · App. 16/487,337 · Granted May 10, 2022

Periodontal gel composition and method of use

Inventors: Keren Mevorat Kaplan (Ness Ziona, IL); Dadi Segal (Tel-Aviv, IL); Danny Rosenbaum (Kfar Saba, IL); Igal Liapis (Vaughan, CA); Igor Makarovsky (Holon, IL); Meir Stern (Rehovot, IL)
Assignee: PRUDENTIX LTD.
A61K31/728A61K9/0014A61K9/06A61K31/444A61K47/32A61P1/02A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,324,772
App. No.
16/487,337
Granted
May 10, 2022
Kind
B2
Abstract

The present invention relates to a periodontal gel composition, more particularly to a liquid composition having a low viscosity at ambient temperature, which upon warming to body temperature solidifies into a viscous gel and then releases a therapeutic agent, e.g., an antibacterial agent, in a sustained release manner; and to a method of use.

Claims (27)

1. A liquid composition comprising a non-biodegradable thermosensitive pharmaceutically acceptable poloxamer copolymer, hyaluronic acid or a salt thereof, and optionally a therapeutic agent,

wherein said copolymer is present in said composition in an amount of from 21% to 32% by weight; said hyaluronic acid has a molecular weight of up to 50000 Da, and said hyaluronic acid or salt thereof is present in said composition in an amount of from 0.01% to 10% by weight; said composition is free of hyaluronic acid with a molecular weight greater than 50000 Da; and said composition has a viscosity of 100-2000 centipoise (cP) at 20° C., when measured with Brookfield viscosimeter RVDV −|+, at either spindle number 03 and 100 rpm, or spindle number 05 and 20 rpm; and upon warming to body temperature, said composition solidifies into a viscous gel and then releases said hyaluronic acid and said therapeutic agent, when present, in a sustained release manner.

2. The composition of claim 1 , wherein said poloxamer copolymer is poloxamer 407, poloxamer 188, poloxamer 124, poloxamer 237, poloxamer 338, or a combination thereof.

3. The composition of claim 2 , wherein said poloxamer copolymer is poloxamer 407.

4. The composition of claim 1 , wherein said poloxamer copolymer is present in said composition in an amount of from 22% to 30% by weight.

5. The composition of claim 1 , wherein said hyaluronic acid has a molecular weight of from 3000 to 50000 Da.

6. The composition of claim 1 , wherein said hyaluronic acid or salt thereof is present in said composition in an amount of from 0.05% to 10% by weight.

7. The composition of claim 1 , wherein the ratio between said poloxamer copolymer and said hyaluronic acid or salt thereof is in a range of from 20:1 to 50:1 by weight.

8. The composition of claim 1 , wherein said therapeutic agent is present and selected from an antimicrobial agent, antibacterial agent, antifungal agent, anti-inflammatory agent, or anti-pain agent.

9. The composition of claim 8 , wherein said therapeutic agent is an antibacterial agent.

10. The composition of claim 9 , wherein said antibacterial agent is a topical antibacterial agent selected from a quaternary ammonium compound, a guanidine compound, hexetidine, octenidine, or a pharmaceutically acceptable salt thereof.

11. The composition of claim 10 , wherein said quaternary ammonium compound is benzalkonium chloride, or cetylpyridinium chloride; and said guanidine compound is alexidine, or polyhexamethylene biguanide.

12. The composition of claim 10 , wherein said antibacterial agent is octenidine, or a pharmaceutically acceptable salt thereof.

13. The composition of claim 9 , wherein said antibacterial agent is present at a concentration of from 0.01% to 5% by weight.

14. The composition of claim 1 , wherein said hyaluronic acid has a molecular weight of from 3000 to 50000 Da; and said therapeutic agent is an antibacterial agent.

15. The composition of claim 14 , wherein said poloxamer copolymer is poloxamer 407, poloxamer 188, poloxamer 124, poloxamer 237, poloxamer 338, or a combination thereof; and said hyaluronic acid has a molecular weight of from 4000 to 20000 Da.

16. The composition of claim 15 , wherein said poloxamer copolymer is poloxamer 407.

17. The composition of claim 15 , wherein (i) said poloxamer copolymer is present in said composition in an amount of from 22% to 30% by weight; and (ii) said hyaluronic acid or salt thereof is present in said composition in an amount of from 0.05% to 1.0% by weight; and (iii) the ratio between said poloxamer copolymer and said hyaluronic acid or salt thereof is in a range of from 25:1 to 40:1 by weight; and (iv) said antibacterial agent is present at a concentration of from 0.4% to 0.9% by weight.

18. The composition of claim 16 , wherein (i) said poloxamer copolymer is present in said composition in an amount of from 22% to 30% by weight; and (ii) said hyaluronic acid or salt thereof is present in said composition in an amount of from 0.05% to 1.0% by weight; and (iii) the ratio between said poloxamer copolymer and said hyaluronic acid or salt thereof is in a range of from 25:1 to 40:1 by weight; and (iv) said antibacterial agent is present at a concentration of from 0.4% to 0.9% by weight.

19. The composition of claim 14 , wherein said antibacterial agent is octenidine or a pharmaceutically acceptable salt thereof.

20. A method for treatment of periodontal disease, gingival disease, peri-implantitis, or a disease or injury of the oral mucosa, in an individual in need thereof, said method comprising topically administering into a periodontal pocket, gingival pocket, or a pocket resulting from peri-implantitis, or applying on or into the oral mucosa, of said individual, a composition according to claim 1 wherein said therapeutic agent is present, to thereby release said therapeutic agent in said periodontal pocket, gingival pocket, or pocket resulting from peri-implantitis, or on or into said oral mucosa, respectively, in a sustained release manner.

21. The method of claim 20 , wherein said hyaluronic acid has a molecular weight of from 3000 to 50000 Da; and said therapeutic agent is an antibacterial agent.

22. The method of claim 21 , wherein said poloxamer copolymer is poloxamer 407, poloxamer 188, poloxamer 124, poloxamer 237, poloxamer 338, or a combination thereof; and said hyaluronic acid has a molecular weight of from 4000 to 20000 Da.

23. The method of claim 22 , wherein (i) said poloxamer copolymer is present in said composition in an amount of from 22% to 30% by weight; and (ii) said hyaluronic acid or salt thereof is present in said composition in an amount of from 0.05% to 1.0% by weight; and (iii) the ratio between said poloxamer copolymer and said hyaluronic acid or salt thereof is in a range of 25:1 to 40:1 by weight; and (iv) said antibacterial agent is present at a concentration of from 0.4% to 0.9% by weight.

24. The method of claim 21 , wherein said antibacterial agent is octenidine or a pharmaceutically acceptable salt thereof.

25. A kit for delivering a liquid composition into a periodontal pocket, gingival pocket, or a pocket resulting from peri-implantitis, or for applying said liquid composition on or into the oral mucosa, said kit comprising a composition according to claim 1 ; and a delivery means for topically administering said composition into said periodontal pocket, gingival pocket, or pocket resulting from peri-implantitis, or for applying said composition on or into said oral mucosa.

26. The kit of claim 25 , wherein said delivery mean is a syringe, or an applicator.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2019
From: KAPLAN, KEREN MEVORAT; SEGAL, DADI; ROSENBAUM, DANNY; LIAPIS, IGAL; MAKAROVSKY, IGOR; STERN, MEIR
To: PRUDENTIX LTD.
Reel/Frame 050923/0351 →
Priority Claims (1)
IL 250853 · Feb 28, 2017 · national
Continuity (1)
Related Publication 20200054667A1 · Feb 20, 2020